| abstract |
The present invention relates to novel compounds that are A2A adenosine receptor antagonists of the formula I, and to their use in treating mammals for various disease states, such as obesity, CNS disorders, including the 'movement disorders' (Parkinson's disease, Huntington's Chorea, and catelepsy), and cerebral ischemia, excitotoxicity, cognitive and physiological disorders, depression, ADHD, and drug addiction (alcohol, amphetamine, cannabinoids, cocaine, nicotine, and opioids) and to their use in the enhancement of immune response. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them. |